A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma

Cancer

Volumn 80, Issue 1, 1997, Pages 42-49

  Kimura, Hideki ^a   Yamaguchi, Yutaka ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Adoptive immunotherapy; Interleukin 2; Lung carcinoma; Lymphokine activated killer cells

Indexed keywords

INTERLEUKIN 2;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LUNG CANCER; LUNG RESECTION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 0030926495     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H     Document Type: Article

References (35)

1. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.
2. Mountain CF. The biological operability of stage III non-small cell lung cancer. Ann Thorac Surg 1985;40:60-4.
3. Sadeghi A, Payne D, Rubinstein L, Lad T, and the Lung Cancer Study Group. Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. Int J Radiat Oncol Biol Phys 1988;15:89-97.
4. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106:703-8.
5. Dautzenberg B, Chastang C, Arriagada R, Chevalier TL, Belpomme D, Hurdebourcq M, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. Cancer 1995;76:779-86.
6. Holmes EC, Gail M. Surgical adjuvant therapy for Stage II and Stage IIIA adenocarcinoma and large cell undifferentiated carcinoma. J Clin Oncol 1986;4:710-5.
7. Holmes EC. Adjuvant treatment in resected lung cancer. Semin Surg Oncol 1990;6:263-7.
8. Campbell AC, Hersey P, Harding B, Hollingsworth PM, Skinner J, Maclennan ICM. Effects of anti-cancer agents on immunological status. Br J Cancer 1973;28(Suppl):254-61.
9. Roth JA, Eilber FR, Morton DL. Effect of Adriamycin and high-dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Cancer 1978;41:814-19.
10. Kimura H, Yamaguchi Y. Survival of noncuratively resected lung cancer. Lung Cancer 1994;11:229-42.
11. Kimura H. Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after non-curative resection of primary lung cancer. Lung Cancer 1995;13:31-44.
12. Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer. Lung Cancer 1996;14:301-14.
13. Kimura H, Yamaguchi Y, Fujisawa T. Cytotoxicity of autologous and allogeneic lymphocytes against cultured human lung cancer cells: optimal conditions for the production of cytotoxic lymphocytes. Jpn J Cancer Res 1984;75:1006-16.
14. Kimura H, Yamaguchi Y. Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells. Jpn J Clin Oncol 1989;19:222-8.
15. Sekiya S, Iijima N, Oosaki T, Takamizawa H, Tokita H. A newly developed in vitro chemosensitivity test (nuclear damage assay): application to ovarian cancer. Gynecologic Oncol 1991;40:138-43.
16. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N Eng J Med 1985;313:1486-92.
17. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
18. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-32.
19. McCabe MS, Stablein D, Hawkins MJ. The modified group C experience: Phase III randomized trials of IL-2 versus IL-2/LAK in advanced renal cell carcinoma and advanced melanoma [abstract]. Proc Am Soc Clin Oncol 1991;10:213.
20. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
21. Kedar E, Klein E. Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Cancer Res 1992;59:245-322.
22. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
23. Hayes RL, Koslow M, Hiesinger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995;76:840-52.
24. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment: immunotherapy realized. Cancer 1990;65:800-14.
25. North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 1984;35:89-155.
26. Greenberg PD, Klarnet JP, Kern DE, Cheever MA. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 1988;32:104-27.
27. North RJ. Down regulation of the anti-tumor immune response. Adv Cancer Res 1985;45:1-43.
28. Naor D, Klein BY, Tarcic N, Duke-Cohen JS, editors. Immunosuppression and human malignancy. Clifton, NJ: Humana Press, 1989.
29. Kedar E, Weiss DW. The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 1983;38:171-287.
30. Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: Are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 1990;82:361-70.
31. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994;91:4930-4.
32. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995;166:236-46.
33. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988;6:409-24.
34. Mitchell MS. Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 1988;80:1445-50.
35. Bergmann L. Malignant melanoma: prognosis and actual treatment strategies with chemotherapy and biological response modifiers. Eur J Cancer Clin Oncol 1989;25(Suppl):S31-6.